Juno Therapeutics, a Subsidiary of Celgene
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Juno Therapeutics, a Subsidiary of Celgene sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Juno Therapeutics, a Subsidiary of Celgene: 11 sponsored US clinical trials, 1 recruiting.
Juno Therapeutics, a Subsidiary of Celgene sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Small Lymphocytic, with 1 trials.
Top-decile sponsor footprint
Juno Therapeutics, a Subsidiary of Celgene ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
11 total, page 1 of 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT03331198
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04674813
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04394650
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT04231747
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
NCT03744676
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
NCT03483103
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
NCT03436771
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT03430011
Long-Term Follow-up Study for Patients Previously Treated With JCAR015
NCT02813252
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
NCT02631044
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT02535364
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Juno Therapeutics, a Subsidiary of Celgene pipeline
1 recruiting of 11 indexed (9% open); 8 completed (73%).
Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Lymphoma, Small Lymphocytic (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Juno Therapeutics, a Subsidiary of Celgene: open-pipeline peers nationwide
Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Juno Therapeutics, a Subsidiary of Celgene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 trials (± recruiting share)
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Alkermes · 9% recruiting · 66 trials
- DBV Technologies · 9% recruiting · 11 trials
- Florida Gulf Coast University · 9% recruiting · 11 trials
- Genfit · 9% recruiting · 11 trials
Related
What to do with this Juno Therapeutics, a Subsidiary of Celgene page
11 registered trials is a research-attention snapshot, not an endorsement of Juno Therapeutics, a Subsidiary of Celgene or any single study.
- 1 of Juno Therapeutics, a Subsidiary of Celgene's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lymphoma, Small Lymphocytic is the condition Juno Therapeutics, a Subsidiary of Celgene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Small Lymphocytic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Juno Therapeutics, a Subsidiary of Celgene pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.